Please login to the form below

Not currently logged in

The Accenture Award for Company of the Year (>£150m)



Summary of work

With operations in 180 countries worldwide, Pfizer is a leading global pharmaceutical company. Its diversified global healthcare portfolio includes human and animal biologics, small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.

The company has a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas.

Pfizer is executing a comprehensive R&D strategy to become the biopharmaceutical industry leader in translating advanced science into novel medicines and vaccines that matter most to people. Since 2010, scientists in Pfizer’s Worldwide Research and Development (WRD) organisation have advanced this strategy across three horizons – delivering the Pfizer portfolio, innovating new capabilities and creating the R&D ecosystem of the future.

Pfizer conducts research in cardiovascular, metabolic and endocrine diseases; neuroscience; oncology; vaccines; pain and sensory disorders; immunology and autoimmunity; inflammation and remodelling; and orphan and genetic diseases. Biotech units Rinat and CovX complement the R&D portfolio with unique expertise in monoclonal antibodies and antibody drug conjugates.

It has an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

Judges comments

"Pfizer demonstrated excellent cohesion and is obviously very solid since the Wyeth merger. The new operating model has gone well and there is strong and robust management clearly at the helm.”

Key dates

Entry deadline 26 August 2021
Extended entry deadline 2 September 2021*
*additional fee applies
Judging Day 1 October 2021
Company of the Year Interviews 22 October 2021
PMEA Event 24 November 2021